Literature DB >> 17680823

Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study.

D Vincenti1, S Carrara, O Butera, F Bizzoni, R Casetti, E Girardi, D Goletti.   

Abstract

Tuberculosis is the most frequent co-infection in human immunodeficiency virus (HIV)-infected individuals, and which still presents diagnostic difficulties. Recently we set up an assay based on interferon (IFN)-gamma response to region of difference 1 (RD1) peptides selected by computational analysis which is associated with active Mycobacterium tuberculosis replication. The objective of this study was to investigate the response to RD1 selected peptides in HIV-1-infected individuals in a clinical setting. The mechanisms of this immune response and comparison with other immune assays were also investigated. A total of 111 HIV-infected individuals with symptoms and signs consistent with active tuberculosis were enrolled prospectively. Interferon (IFN)-gamma responses to RD1 selected peptides and recall antigens were evaluated by enzyme-linked immunospot assay. Results were correlated with CD4(+) T cell counts, individuals' characteristics, tuberculin skin test, QuantiFERON-TB Gold and T-SPOT.TB. Results from 21 (19%) individuals were indeterminate due to in vitro cell anergy. Among 'non-anergic' individuals, sensitivity for active tuberculosis of the assay based on RD1 selected peptides was 67% (24 of 36), specificity was 94% (three of 54). The assay also resulted positive in cases of extra-pulmonary and smear-negative pulmonary active tuberculosis. The response was mediated by CD4(+) effector/memory T cells and correlated with CD4(+) T cell counts, but not with plasma HIV-RNA load. Moreover, the RD1 selected peptides assay had the highest diagnostic odds ratio for active tuberculosis compared to tuberculin skin test (TST), QuantiFERON-TB Gold and T-SPOT.TB. RD1 selected peptides assay is associated with M. tuberculosis replication in HIV-infected individuals, although T cell anergy remains an important obstacle to be overcome before the test can be proposed as a diagnostic tool.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17680823      PMCID: PMC2219274          DOI: 10.1111/j.1365-2249.2007.03462.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Comparison of a tuberculin interferon-gamma assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection.

Authors:  P J Converse; S L Jones; J Astemborski; D Vlahov; N M Graham
Journal:  J Infect Dis       Date:  1997-07       Impact factor: 5.226

2.  Differential T cell responses to Mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors.

Authors:  T Ulrichs; M E Munk; H Mollenkopf; S Behr-Perst; R Colangeli; M L Gennaro; S H Kaufmann
Journal:  Eur J Immunol       Date:  1998-12       Impact factor: 5.532

3.  Tuberculin sensitivity: conversions and reversions in a rural African population.

Authors:  P E Fine; J Bruce; J M Ponnighaus; P Nkhosa; A Harawa; E Vynnycky
Journal:  Int J Tuberc Lung Dis       Date:  1999-11       Impact factor: 2.373

4.  Rapid diagnostic tests for tuberculosis: what is the appropriate use? American Thoracic Society Workshop.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1997-05       Impact factor: 21.405

5.  Comparative genomics of BCG vaccines by whole-genome DNA microarray.

Authors:  M A Behr; M A Wilson; W P Gill; H Salamon; G K Schoolnik; S Rane; P M Small
Journal:  Science       Date:  1999-05-28       Impact factor: 47.728

Review 6.  Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review.

Authors:  Madhukar Pai; Lee W Riley; John M Colford
Journal:  Lancet Infect Dis       Date:  2004-12       Impact factor: 25.071

7.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.

Authors:  C Dye; S Scheele; P Dolin; V Pathania; M C Raviglione
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

8.  A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10).

Authors:  Fransois-Xavier Berthet; Peter Birk Rasmussen; Ida Rosenkrands; Peter Andersen; Brigitte Gicquel
Journal:  Microbiology (Reading)       Date:  1998-11       Impact factor: 2.777

9.  Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis.

Authors:  P Ravn; A Demissie; T Eguale; H Wondwosson; D Lein; H A Amoudy; A S Mustafa; A K Jensen; A Holm; I Rosenkrands; F Oftung; J Olobo; F von Reyn; P Andersen
Journal:  J Infect Dis       Date:  1999-03       Impact factor: 5.226

10.  Effect of non-tuberculous Mycobacteria infection on tuberculin results among primary school children in Kenya.

Authors:  D O Kwamanga; O B Swai; R Agwanda; W Githui
Journal:  East Afr Med J       Date:  1995-04
View more
  25 in total

1.  ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment.

Authors:  Stefania Girlanda; Paola Mantegani; Elena Baldissera; Patrizia Aiello; Manuela Ratti; Maria Grazia Sabbadini; Claudio Fortis
Journal:  Clin Rheumatol       Date:  2010-07-20       Impact factor: 2.980

2.  Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients.

Authors:  Mi Ra Ryu; Min-Seung Park; Eun Hye Cho; Chul Won Jung; Kihyun Kim; Seok Jin Kim; Ha Young Oh; Wooseong Huh; Hye Ryoun Jang; Won-Jung Koh; Hye Yun Park; Young-Ho Kim; Dong Hyun Sinn; Jin-Oh Choi; Jae-Won Joh; Jong Man Kim; Sung Joo Kim; Jae Berm Park; Eun-Suk Kang
Journal:  J Clin Microbiol       Date:  2018-10-25       Impact factor: 5.948

Review 3.  Laboratory Diagnosis of Extra-pulmonary Tuberculosis (EPTB) in Resource-constrained Setting: State of the Art, Challenges and the Need.

Authors:  Manju Purohit; Tehmina Mustafa
Journal:  J Clin Diagn Res       Date:  2015-04-01

4.  Evaluation of QuantiFERON-TB gold in-tube and tuberculin skin tests among immigrant children being screened for latent tuberculosis infection.

Authors:  Meredith M Howley; John A Painter; Dolores J Katz; Edward A Graviss; Randall Reves; Suzanne F Beavers; Denise O Garrett
Journal:  Pediatr Infect Dis J       Date:  2015-01       Impact factor: 2.129

5.  Role of interferon-gamma release assays in the diagnosis of pulmonary tuberculosis in patients with advanced HIV infection.

Authors:  Adithya Cattamanchi; Isaac Ssewenyana; J Lucian Davis; Laurence Huang; William Worodria; Saskia den Boon; Samuel Yoo; Alfred Andama; Philip C Hopewell; Huyen Cao
Journal:  BMC Infect Dis       Date:  2010-03-20       Impact factor: 3.090

6.  Serial interferon-gamma release assays during treatment of active tuberculosis in young adults.

Authors:  Sei Won Lee; Choon-Taek Lee; Jae-Joon Yim
Journal:  BMC Infect Dis       Date:  2010-10-16       Impact factor: 3.090

Review 7.  New diagnostic methods for tuberculosis.

Authors:  Melissa R Nyendak; Deborah A Lewinsohn; David M Lewinsohn
Journal:  Curr Opin Infect Dis       Date:  2009-04       Impact factor: 4.915

8.  Comparison of QFT-Plus and QFT-GIT tests for diagnosis of M. tuberculosis infection in immunocompetent Korean subjects.

Authors:  Ji Young Hong; So Yeong Park; Ahreum Kim; Sang-Nae Cho; Yun-Gyoung Hur
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

9.  The impact of HIV infection and CD4 cell count on the performance of an interferon gamma release assay in patients with pulmonary tuberculosis.

Authors:  Martine G Aabye; Pernille Ravn; George PrayGod; Kidola Jeremiah; Apolinary Mugomela; Maria Jepsen; Daniel Faurholt; Nyagosya Range; Henrik Friis; John Changalucha; Aase B Andersen
Journal:  PLoS One       Date:  2009-01-19       Impact factor: 3.240

10.  Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection.

Authors:  Elisa Petruccioli; Teresa Chiacchio; Assunta Navarra; Valentina Vanini; Gilda Cuzzi; Claudia Cimaglia; Luigi Ruffo Codecasa; Carmela Pinnetti; Niccolò Riccardi; Fabrizio Palmieri; Andrea Antinori; Delia Goletti
Journal:  J Infect       Date:  2020-02-22       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.